Skip to main content
SpringerLink
Log in

Bortezomib in the Treatment of Multiple Myeloma

  • Book
  • © 2011

Overview

Editors:
  1. Irene M. Ghobrial

    1. Dana-Farber Cancer Institute, Dept. Medical Oncology, Harvard Medical School, Boston, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  2. Paul G. Richardson

    1. Dana-Farber Cancer Institute, Dept. Medical Oncology, Harvard Medical School, Boston, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  3. Kenneth C. Anderson

    1. Dana-Farber Cancer Institute, Dept. Medical Oncology, Harvard Medical School, Boston, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  • Contemporary monograph on Bortezomib and the proteasome discovery from the lab to the clinic
  • A valuable source of information for researchers and clinicians from the fields of oncology and pharmacology
  • Depicts the biochemical background of the drug action

Part of the book series: Milestones in Drug Therapy (MDT)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (11 chapters)

  1. Front Matter

    Pages i-viii
    Download chapter PDF

  2. Bortezomib’s Scientific Origins and Its Tortuous Path to the Clinic

    • Alfred L. Goldberg
    Pages 1-27

  3. Preclinical Activities of Bortezomib in MM, the Bone Marrow Microenvironment and Pharmacogenomics

    • Teru Hideshima, Paul G. Richardson, Kenneth C. Anderson
    Pages 29-42

  4. Bortezomib and Osteoclasts and Osteoblasts

    • Michal T. Krauze, G. David Roodman
    Pages 43-52

  5. Bortezomib in the Upfront Treatment of Multiple Myeloma

    • Jesús F. San Miguel, María -Victoria Mateos
    Pages 53-68

  6. The Use of Bortezomib in Autologous Transplantation for Multiple Myeloma

    • Amelia A. Langston, Sagar Lonial
    Pages 69-77

  7. Bortezomib in Relapsed and Relapsed/Refractory Multiple Myeloma

    • Jatin J. Shah, Robert Z. Orlowski
    Pages 79-94

  8. Bortezomib-Induced Peripheral Neuropathy in Multiple Myeloma: Principles of Identification and Management

    • Jacob P. Laubach, Paul G. Richardson
    Pages 95-105

  9. Bortezomib in Mantle Cell Lymphoma

    • Andre Goy
    Pages 107-121

  10. Bortezomib in Waldenstrom’s Macroglobulinemia

    • Irene M. Ghobrial, Aldo M. Roccaro, Xavier Leleu
    Pages 123-133

  11. Bortezomib in Systemic Light-Chain Amyloidosis

    • Morie A. Gertz, Raymond Comenzo
    Pages 135-148

  12. Second-Generation Proteasome Inhibitors

    • Dixie-Lee Esseltine, Larry Dick, Erik Kupperman, Mark Williamson, Kenneth C. Anderson
    Pages 149-176

  13. Back Matter

    Pages 177-179
    Download chapter PDF
Back to top

Keywords

About this book

Multiple Myeloma (MM) is the second most common type of blood cancer, resulting from an overproduction of cancerous infection-fighting white blood cells, known as plasma cells. Plasma cells are a crucial part of the immune system responsible for the production of antibodies. Bortezomib is a promising anticancer drug targeting the proteasome. This proteasome inhibitor induces cell stress and apoptosis in the cancer cells. While multiple mechanisms are likely to be involved, proteasome inhibition may prevent the degradation of pro-apoptotic factors, permitting activation of programmed cell death in neoplastic cells dependent upon the suppression of proapoptotic pathways. This monograph on bortezomib is a valuable source of information for researchers and clinicians from the fields of oncology and pharmacology, working either in academia or the pharmaceutical industry.

Editors and Affiliations

  • Dana-Farber Cancer Institute, Dept. Medical Oncology, Harvard Medical School, Boston, USA

    Irene M. Ghobrial, Paul G. Richardson, Kenneth C. Anderson

Bibliographic Information

Publish with us

Policies and ethics

Back to top

Search

Navigation